This week's sponsor is Navitas. | | | Top Stories Monday, July 18, 2016 Evoke Pharma saw its shares nose-dive by more 75% after it disclosed that a Phase III study for its nasal formulation of metoclopramide to treat diabetic gastroparesis symptoms in adult women failed to meet its primary endpoint. Monday, July 18, 2016 One of AstraZeneca’s key drugs for its ambitious sales target Tagrisso (osimertinib) has hit its marks in a Phase III test for certain lung cancer patients--passing a key FDA confirmatory study request. Monday, July 18, 2016 Bayer has partnered with micro-cap diagnostics player T2 Biosystems as part of its R&D efforts in blood coagulation. The pair will develop tools and assays to drive drug discovery and advance biomarkers for certain Bayer hemostasis-related programs. Monday, July 18, 2016 Rumors of staff cuts from AstraZeneca’s MedImmune biologics arm are part of previously stated changes and a deeper focus (and a larger cash pile) for its oncology research. Sunday, July 17, 2016 George Freeman has been moved on from the post of minister for life sciences as part of a reshuffle initiated by new U.K. Prime Minister Theresa May in the wake of the Brexit vote. The rejig leaves the life sciences sector at least temporarily without a dedicated minister--but with an ally in a key policy role--at a time when it is trying to shape the outcome of the vote to leave the European Union. | Germany’s Merck has seen the EMA accept for review its marketing application for the oral multiple sclerosis drug cladribine. Statement Bristol-Myers Squibb could soon see an expanded use of PD-1 cancer drug Opdivo in the U.S. and Europe for patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck. Release BrainStorm has posted positive top-line results from its U.S. Phase II study of NurOwn in ALS patients. Statement EMA is to review Samsung Bioepis' Humira biosimilar application. FiercePharmaAsia story Seattle Genetics and Takeda have published final data from their Adcetris monotherapy Phase II in relapsed or refractory classical Hodgkin lymphoma. Release | |
| Resources Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. This series provides an overview of the science and technology used to enable discovery and the processes scientists use to discover new therapeutics. Download now. Sponsored by: Speid & Associates, Inc. Do you have what it takes? Drug Development training does not have to be boring. The Drug Development Boot CampTM trains experienced researchers and drug developers in all major aspects of drug development, using an accelerated learning and total immersion approach. Click here to website. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA Characterization of Animal Models for Alzheimer’s disease: Webinar Presented by Charles River July 19, 2016 Master of Science in Bioinformatics at Northeastern University Fall 2016, Spring 2017 Courses BIOSPAIN 2016 September 28-30, 2016 | Bilbao, Basque Country, Spain FierceBiotech Drug Development Forum September 19-21, 2016 | Boston, MA Immunotherapy: Mapping the future July 28, 2016 | Foster City, CA BioImmersion: In Depth Biotech for the Non-Scientist October 5-7, 2016 | Chicago, IL |